PRKDC
protein-codingprotein kinase, DNA-activated, catalytic subunit, the group of Armadillo like helical domain containing
Gene summary
This gene encodes the catalytic subunit of the DNA-dependent protein kinase (DNA-PK). It functions with the Ku70/Ku80 heterodimer protein in DNA double strand break repair and recombination. The protein encoded is a member of the PI3/PI4-kinase family.[provided by RefSeq, Jul 2010]
- HYRC
- HYRC1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~187.1 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0014423
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0014423
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0014423
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014423
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0014423
Submitter: ClinGen
PRKDC was first reported in relation to autosomal recessive combined immunodeficiency due to DNA-PKcs deficiency in 2009 (van der Burg et al., PMID: 1907532). The phenotype of patients with DNA-PKcs deficiency can be variable but may include: a spectrum of combined immunodeficiency, recurrent infections, progressive pulmonary disease, growth retardation, dysmorphic facies, neurologic abnormalities, and autoimmunity. PRKDC encodes the catalytic subunit of a nuclear DNA-dependent serine/threonine protein kinase (DNA-PK) which is involved in NHEJ during DNA double-strand break (DSB) repair and for V(D)J recombination during immune development. Patients with hypomorphic mutations, with partially preserved T and B cell development, can present with signs of autoimmunity owing to the role of DNA-PKcs in regulating expression of AutoImmune-Regulator (AIRE)-dependent peripheral tissue antigens during thymocyte selection. It is a rare inborn error of immunity. Thus far, pathogenic missense variations and splicing abnormalities have been reported in several publications (PMIDs: 19075392, 23722905, 30121298, 25842288, 26546606, 26122175, 30778343, 29921932) and many are included in this curation. Nonsense or frameshift variants have not yet been described in humans. The mechanism of pathogenicity is reported to be hypomorphic loss of function. Heterozygous carriers have not been shown to have a clinical phenotype. This gene-disease association is also supported by accompanying experimental evidence in both PRKDC-deficient patients (PMIDs 19075392, 23722905, 26546606). and animal models (PMIDs 8524788, 11489998, 22981234, 27566103). In summary, PRKDC is definitively associated with autosomal recessive combined immunodeficiency due to DNA-PKcs deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen SCID/CID GCEP on November 18, 2021 (SOP Version 8).
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious; Craniofacial; Neurologic
Intervention: Allergy/Immunology/Infectious
Rationale: Antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; BMT has been reported
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PRKDC variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_006904.7. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 21 | 1430 | 15 | 1466 | ||
| missense | 2 | 1 | 2593 | 126 | 14 | 2736 |
| nonsense | 6 | 6 | ||||
| start loss | 0 | |||||
| frameshift | 1 | 5 | 2 | 8 | ||
| splice donor/acceptor (+/-2bp) | 26 | 26 | ||||
| Total | 2 | 2 | 2651 | 1556 | 31 | 4242 |
Highest pathogenic variant AF is 0.000010267137
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_008835.5 | 86 | MANE Select | |
| Ensembl | ENSP00000313420.3 | 86 | MANE Select | |
| RefSeq | NP_001075109.1 | 85 | Standard | |
| Ensembl | ENSP00000345182.4 | 85 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| prkdc | Danio rerio | Structure: neutrophil Quality: increased amount abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Cell cycle - Homo sapiens (human)
- Non-homologous end-joining - Homo sapiens (human)
- Cell Cycle
- miRNA Regulation of DNA Damage Response
- Retinoblastoma (RB) in Cancer
Biological Process
- telomere maintenance
- somitogenesis
- negative regulation of protein phosphorylation
- activation of innate immune response
- B cell lineage commitment
Molecular Function
- double-stranded DNA binding
- RNA binding
- protein kinase activity
- protein serine/threonine kinase activity
- DNA-dependent protein kinase activity
Cellular Component
- nuclear chromosome, telomeric region
- nucleus
- nucleoplasm
- transcription factor complex
- nucleolus
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000314191
- Coding exons
- 87
- Length
- 187075
- Individuals with no LoFs
- 1885
- Homozygous LoFs
- 122762
- Heterozygous LoFs
- 9
- Defined
- 124656
- p
- 0.877
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.76 | 1727 | 2.08e+3 | 0.830 | 0.000115 | 26967 |
| Missense (PolyPhen) | 396 | 626.8 | 0.63178 | 8333 | ||
| Synonymous | -1.09 | 835 | 796 | 1.05 | 0.0000463 | 7701 |
| Loss of Function | 12.8 | 5 | 201 | 0.0249 | 0.0000103 | 2670 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 1.0 | 0.82 | notable |
| Latino/Admixed American | 1.0 | 0.89 | notable |
| Ashkenazi Jewish | 1.0 | 0.91 | notable |
| East Asian | 1.0 | 0.90 | notable |
| Finnish | 1.0 | 0.91 | notable |
| European (Non-Finnish) | 1.0 | 0.87 | notable |
| South Asian | 1.0 | 0.89 | notable |
| Other | 1.0 | 0.87 | notable |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D. Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an indirect mechanism. Interacts with CRY1 and CRY2; negatively regulates CRY1 phosphorylation. Plays a role in the regulation of DNA virus- mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway. {ECO:0000269|PubMed:12649176, ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:15574326, ECO:0000269|PubMed:28712728, ECO:0000269|PubMed:9679063}.;
- Disease
- DISEASE: Immunodeficiency 26 with or without neurologic abnormalities (IMD26) [MIM:615966]: A form of severe combined immunodeficiency characterized by reduced or absent T and B cells, recurrent candidiasis, and lower respiratory tract infections. Some patients show dysmorphic features, severe growth failure, microcephaly, seizures, and impaired neurological functions. {ECO:0000269|PubMed:19075392, ECO:0000269|PubMed:23722905}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.665
Essentials
- Essential (CRISPR2)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.921
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |